The Joint SLR (Optical Range) and Radar-VLBI Satellite Observations using VIRAC Radio Telescope RT32, RT16 and SLR Station Riga

Abstract Joint VLBI and SLR satellite tracking is a novel tracking approach to explore potential applications and to work out common procedures to coordinate observations between astronomical observatories in Latvia. Global Navigation Satellite System (GNSS) satellites equipped with laser retroreflectors have been chosen as test targets because they are accessible by both measuring techniques – satellite laser ranging (SLR) and Very Long Base Interferometry (VLBI). The first Joint SLR and VLBI observations of selected GNSS satellites using three of Latvian large-scale astronomical utilities – VIRAC radio telescopes RT32 and RT16 (Ventspils International Radio Astronomy Centre of Ventspils U…

220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

Background: IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients ( pts) with heavily pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2…